<DOC>
	<DOCNO>NCT01602562</DOCNO>
	<brief_summary>The purpose study evaluate preventive efficacy HSV infection safety valaciclovir ( VACV ) adult pediatric HSCT patient .</brief_summary>
	<brief_title>Valaciclovir Hydrochloride Phase III Hematopoietic Stem Cell Transplantation Patients</brief_title>
	<detailed_description>This clinical study multicenter open-label study adult pediatric hematopoietic stem cell transplantation ( HSCT ) patient . The primary objective confirm preventive efficacy herpes simplex virus ( HSV ) infection 256U87 ( VACV : valaciclovir ) due treatment immediately hematopoietic stem cell transplantation . The secondary objective confirm safety VACV case use purpose . This clinical study consist follow two period : screening period last 7 day long administration period 7 day HSCT 35 day HSCT ( 43 day total ) . During administration period , adult patient orally give VACV tablet twice daily , pediatric patient orally give VACV granule twice daily dose 25 mg/kg b.w . ( maximum dose per treatment : 500 mg ) . Pediatric patient weigh 40 kg may orally give VACV tablet twice daily .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Patients plan undergo hematopoietic stem cell transplantation , except cord blood transplantation . Patients age 1 65 time inform consent . Patients submit voluntary write informed consent 12 year old . Patient male female . Male patient must willing use adequate contraception study . Female patient childbearing potential must agree consistently perform contraceptive method . QTc &lt; 450 msec , QTc &lt; 480 msec patient bundle branch block . ( value base either single ECG value triplicate ECG average QTc value ) Liver test ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2x upper limit normal ( ULN ) ; alkaline phosphatase ( AlP ) total bilirubin &lt; =1.5xULN ( total bilirubin &gt; 1.5xULN acceptable direct bilirubin &lt; 35 % ) . Patients history HSCT . Patients judge follow condition investigator ( subinvestigator ) : clinical severity malabsorption syndrome , vomit , mucositis gastrointestinal dysfunction serious orally administer VACV absorb . Patients know nucleoside analog hypersensitivity . Patients concurrent past history renal function disorder ( serum creatinine &gt; =1.5x ULN ) . Patients serious complication ( eg , malignant tumour , cardiac disorder , juvenile diabetes ) . Patients currently treat prohibit concomitant drug . Patients evidence chronic hepatitis B C. Patients AIDS patient infect HIV . Patients give trial product within 30 day initiation administration trial product intend participate clinical trial . Patients pregnant probably pregnant . Patients follow protocol psychological , family , social geological reason . Patients allow participate clinical trial investigator ( subinvestigator ) judge participation inappropriate .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Herpes simplex infection</keyword>
	<keyword>valaciclovir</keyword>
	<keyword>herpes simplex virus</keyword>
	<keyword>hematopoietic stem cell transplantation</keyword>
</DOC>